Ettore Novellino, born in Montemarano August 15, 1950, got the laurea at the School of Pharmacy at Napoli University in 1974.
1978-1985 Assistant professor of medicinal chemistry
1985-1994 Associed professor of medicinal chemistry
1994- Full professor of medicinal chemistry
2000- Dean of the School of Pharmacy of Napoli University
From 2003 he is a member of the scientific board of the European Research Centre for Drug Discovery and Development at Siena University.
Starting from 1986, Prof. Novellino spent a lot of time doing research in estimated Institutions:
- Department of Chemistry, Pomona College of Cleremont, California – USA;
- Lab of Molecular Graphics, Dept of Medicinal Chemistry, University of San Francisco, California – USA;
- Lab of Computer Graphics “Abbott Laboratories”, Chicago – USA;
- Centre Computayional Analysis, Freie Universitat of Berlino;
- Centre of Computational Chemistry, School of Pharmacy, University of Zurig.
Member of the Editorial boarding of Journal of Molecular Graphics and Modelling
Prof. Novellino has 200 publications in national and international journals with high impact factor.
1988-1997 Member of Comitato Consultivo CUN (MURST ex 40%).
1996-1998/1999-2001/2002-2004 Member of Commissione di esperti per la valutazione dei progetti di ricerca scientifici, prevista dalla Legge Regionale 41/94 (Promozione della Ricerca Scientifica in Campania), representing the University of Salerno and Napoli.
2001-2004 Member of the Commissione di Garanzia (MIUR) to evaluate national grant proposals (PRIN).
Prof. Novellino’s research is focused upon many topics in the field of Medicinal Chemistry:
- design and synthesis of adenosine receptor antagonist ligands; in particular of selective human A3 or A1 adenosine receptor antagonists.
- design and synthesis of new central or peripheral benzodiazepine receptor ligands.
- Homolgy buiding of a5b1 integrin receptor, and design of new potential potent and selective a5b1 antagonists.
- Design and synthesis of new factor VIII agonists.
- Structural studies of peptides responsible of the autoiimune response which characterize the Celiac Sprue.
- Pharmacophore identification of Urotensin II antagonists.
- Synthesis of peptidomimetic analogues of Urotensin-II
- Structural studies of the beta-amyloid peptide (25-35) and design of new anti-Alzheimer agents.
- Building of the extracellular portion of the NMDA receptor and development of new NMDA antagonists.
- Building of a 3D model of the of the NOP opioid receptor. Comparison of the 3D models of different subtype of oppioid receptors, hypothesis of a selectivity theory and design of new NOP antagonists.
- Rational design and development of new potent DNA-intercalating agents as useful chemical compounds in anticancer therapy.
- Rational design and development of new and selective farnesyltransferase inhibitors as useful chemical compounds in anticancer therapy.
- Rational design and development of new potent and selective integrin ligands as useful chemical compounds in anticancer therapy.
- Rational design and development of new potent and selective adenosine deaminase inhibitors as useful chemical compounds in anticancer therapy.
- Rational design and development of new potent and selective aldose reductase inhibitors as useful chemical compounds in the treatment of diabetic complications.
- Rational design and development of new potent and selective A1 adenosine antagonists as useful chemical compounds in the treatment of neurological diseases.
- Rational design and development of new potent and selective integrase inhibitors as useful chemical compounds in the treatment of the acquired immunodeficiency syndrome (AIDS);
- Rational design of new potent and selective antagonists of glutamate NMDA receptor;
- Topology studies of G-protein couple receptors: purinergic, opioid and peptidergic receptors as key studies.
- Topology studies of channel receptors: calcium receptors as key studies.
- Synthesis, characterization and, biological activity of peptides and peptidomimetics actives on Melanocortin System.
- Synthesis of new quinolonic derivatives with anticancer activity.